Drug shows potential widespread efficacy across skin tones

A study explored the safety and efficacy of guselkumab in patients with plaque psoriasis.

In a Phase 3b trial published in JAMA Dermatology, researchers randomly assigned more than 100 adult patients with moderate to severe plaque psoriasis and who did not identify as white to receive either 100 milligrams of subcutaneous guselkumab or placebo. The patients who initially received placebo crossed over to guselkumab at weeks 16 and 20.

The researchers found that 70% and 50% of the patients who received guselkumab achieved clear or almost clear skin and complete skin clearance, respectively. Further, the patients in the guselkumab group experienced greater than 94% improvements in psoriasis body surface area and the Psoriasis Area and Severity Index.

The adverse events reported in the trial — including upper respiratory tract infections and nasopharyngitis — were consistent with those previously known for the drug.

The findings demonstrated that the treatment regimen investigated in the trial could help improve the skin clearance and quality of life of patients with darker skin tones.

Read more: JAMA Dermatology

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.